A STUDY TO EVALUATE THE SAFETY AND FEASIBILITY OF THE COMBINED USE OF NIVOLUMAB WITH PEMETREXED FOR THE TREATMENT OF ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
- Registry ID
- IIT-0009
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- ALBERTA HEALTH SERVICES, CROSS CANCER INSTITUTE
- Start date
- 2020-07-27
- Last update
- 2019-10-30
Conditions
- SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Related clinical trials
- A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND
SAFETY OF PETOSEMTAMAB PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB IN
FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC PD-L1+ HEAD AND NECK
SQUAMOUS CELL CARCINOMA.
- A PHASE 3 OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND
SAFETY OF PETOSEMTAMAB COMPARED WITH INVESTIGATOR¿S CHOICE MONOTHERAPY
TREATMENT IN PREVIOUSLY TREATED PATIENTS WITH INCURABLE, METASTATIC/RECURRENT HEAD
AND NECK SQUAMOUS CELL CARCINOMA
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF FICLATUZUMAB IN
COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND
NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE
DOSTARLIMAB AS SEQUENTIAL THERAPY AFTER CHEMORADIATION IN PARTICIPANTS WITH
LOCALLY ADVANCED UNRESECTED HEAD AND NECK SQUAMOUS CELL CARCINOMA
- A PHASE III, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF VOLRUSTOMIG
(MEDI5752) AS SEQUENTIAL THERAPY VERSUS OBSERVATION IN PARTICIPANTS WITH
UNRESECTED LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, WHO
HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY
(EVOLVE-HNSCC)
- A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY USING A MASTER PROTOCOL TO
EVALUATE NOVEL IMMUNOTHERAPY COMBINATIONS AS FIRST-LINE TREATMENT IN
PARTICIPANTS WITH RECURRENT/METASTATIC PD-L1 POSITIVE SQUAMOUS CELL CARCINOMA
OF THE HEAD AND NECK
View on source registry